SMS Lifesciences India Ltd. AI Stock Analysis
Want to see IN:HALEOSLABS full AI Analyst Report?
SMS Lifesciences India Ltd. (HALEOSLABS) AI Stock Analysis
SMS Lifesciences India Ltd.
(NSE:HALEOSLABS)
Strong balance sheet and price position above moving averages are primary positives; revenue inconsistencies and cash flow volatility are the main constraints.
SMS Lifesciences India Ltd. (HALEOSLABS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 4.81B
- Dividend Yield
- 0.09%
- Average Volume (3M)
- 90
- Price to Earnings (P/E)
- 37.1
- Beta (1Y)
- 0.99
- Revenue Growth
- -0.99%
- EPS Growth
- -30.72%
- Country
- India
- Employees
- 611
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
SMS Lifesciences India Ltd. Business Overview & Revenue Model
Company Description
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applicatio...
SMS Lifesciences India Ltd. Financial Statement Overview
Summary
Inconsistent revenue growth and margin volatility offset by solid balance sheet expansion with growing equity and improving operating cash flow.
Income Statement
45NeutralBalance Sheet
75PositiveCash Flow
50Neutral| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.47B | 3.34B | 3.37B | 3.00B | 3.13B | 2.65B |
| Gross Profit | 893.12M | 480.08M | 1.17B | 907.68M | 845.45M | 408.72M |
| EBITDA | 363.12M | 446.77M | 496.44M | 347.37M | 338.06M | 319.58M |
| Net Income | 145.41M | 173.12M | 201.09M | 90.93M | 114.63M | 135.57M |
Balance Sheet | ||||||
| Total Assets | 0 | 4.54B | 3.90B | 3.91B | 3.95B | 3.05B |
| Cash, Cash Equivalents and Short-Term Investments | 11.92M | 23.69M | 15.08M | 14.93M | 36.10M | 110.64M |
| Total Debt | 0 | 1.11B | 864.09M | 1.01B | 1.00B | 651.63M |
| Total Liabilities | -2.03B | 2.25B | 1.78B | 1.98B | 2.07B | 1.76B |
| Stockholders Equity | 2.03B | 2.14B | 1.97B | 1.77B | 1.69B | 1.29B |
Cash Flow | ||||||
| Free Cash Flow | 262.34M | -228.98M | 187.06M | 34.38M | -338.56M | -25.15M |
| Operating Cash Flow | 457.63M | 349.64M | 340.55M | 243.06M | 146.95M | 330.42M |
| Investing Cash Flow | -192.05M | -579.69M | -149.98M | -184.50M | -312.92M | -266.22M |
| Financing Cash Flow | -262.87M | 237.10M | -191.24M | -65.64M | 168.88M | -310.00K |
SMS Lifesciences India Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HALEOSLABS, the sentiment is Positive. The current price of 1590.00 is above the 20-day moving average (MA) of 1491.24, above the 50-day MA of 1502.27, and above the 200-day MA of 1443.56, indicating a bullish trend. The MACD of -6.52 indicates Negative momentum. The RSI at 58.93 is Neutral, neither overbought nor oversold. The STOCH value of 54.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HALEOSLABS.
SMS Lifesciences India Ltd. Peers Comparison
Overall Rating
IN:SUPRIYA62Neutral
IN:CONCORDBIO60.75Neutral
IN:SYNGENE60.6Neutral
IN:HALEOSLABS60Neutral
IN:DCAL57Neutral
IN:BIOCON47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | INR 50.90B | 28.73 | ― | 0.16% | 23.00% | -2.84% | |
| 61Neutral | INR 124.39B | 44.12 | ― | 1.27% | 4.02% | -12.81% | |
| 61Neutral | INR 179.51B | 95.68 | ― | 0.28% | -5.99% | -60.30% | |
| 60Neutral | INR 4.81B | 37.08 | ― | 0.09% | -0.99% | -30.72% | |
| 57Neutral | INR 27.26B | 39.88 | ― | ― | -20.86% | -34.51% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | INR 597.19B | 121.75 | ― | 0.14% | 5.70% | -24.72% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:HALEOSLABS | SMS Lifesciences India Ltd. | 1590.00 | 262.10 | 19.74% | |
| IN:BIOCON | Biocon Limited | 366.80 | -54.30 | -12.89% | |
| IN:CONCORDBIO | Concord Biotech Ltd. | 594.50 | -151.06 | -20.26% | |
| IN:DCAL | Dishman Carbogen Amcis Ltd. | 173.90 | -74.15 | -29.89% | |
| IN:SUPRIYA | Supriya Lifescience Limited | 632.40 | -169.95 | -21.18% | |
| IN:SYNGENE | Syngene International Ltd. | 444.70 | -196.29 | -30.62% |
SMS Lifesciences India Ltd. Corporate Events
Haleos Labs Confirms All Resolutions Passed at 20th AGM Held Online
Haleos Labs Limited has reported the voting results of its 20th Annual General Meeting held on September 30, 2026, which was conducted via video conferencing. A total of 58 shareholders, including members of the promoter group and public shareholders...
Haleos Labs’ Mahi Drugs Unit Clears USFDA Inspection with No Observations
Haleos Labs Limited announced that the United States Food and Drug Administration has successfully completed an inspection of its material subsidiary Mahi Drugs Private Limited’s API manufacturing facility at Jawaharlal Nehru Pharma City in Andhra Pr...
Haleos Labs Sets 20th AGM to Approve FY26 Results, Dividend and New Auditor
Haleos Labs Limited has convened its 20th Annual General Meeting for September 30, 2026, to be conducted via video conferencing and other audio-visual means, reflecting ongoing use of digital platforms for shareholder engagement. Shareholders will re...
Haleos Labs Publishes Notices for 20th AGM in Line with SEBI Norms
Haleos Labs Limited, formerly SMS Lifesciences India Ltd., is a Hyderabad-based pharmaceutical and life sciences company listed on BSE and NSE under the symbol HALEOSLABS. It uses regional and national business newspapers to disseminate investor info...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
